Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

(2013) T. M. A. Abdel-Fatah et al.   ANNALS OF ONCOLOGY

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma

(2013) Sun Young Kwon et al.   HISTOPATHOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic influence of BCL2 expression in breast cancer

(2012) Ki-Tae Hwang et al.   INTERNATIONAL JOURNAL OF CANCER

Assessment of Predictive Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2011) Mallika Tewari et al.   Asian Journal of Surgery

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors

(2011) Kareem Tawfik et al.   HUMAN PATHOLOGY

Different Prognostic Significance of Bcl-2 Based on Cancer Molecular Subtype

(2011) Ju-Young Lee et al.   Journal of Breast Cancer

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer

(2011) H Raza Ali et al.   JOURNAL OF PATHOLOGY

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

(2010) Yoon-La Choi et al.   BMC CANCER

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

(2010) S-J Dawson et al.   BRITISH JOURNAL OF CANCER

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterogeneity of Bcl-2 expression in metastatic breast carcinoma

(2010) Andrea Proctor Subhawong et al.   MODERN PATHOLOGY

Bcl2 family proteins in carcinogenesis and the treatment of cancer

(2009) Anna Frenzel et al.   APOPTOSIS

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

(2009) Grace M Callagy et al.   BMC CANCER

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

(2008) Jiyoung Rhee et al.   BMC CANCER